Background: Presently, few options are available for refractory colorectal cancer (CRC). O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation is a frequent and early event in CRC tumourigenesis. This epigenetic silencing is a predictor of response to the alkylating drug temozolomide in glioblastoma. Preclinical evidences and some case reports showed temozolomide activity in CRC with MGMT silencing, but the available data from clinical trials are inconsistent. Methods: This was a multicentre, phase 2 trial, planned according to a two-stage Simon's optimal design to investigate activity and safety of temozolomide in refractory CRC harbouring MGMT promoter methylation. The primary end point was overall response rate (ORR). Patients who failed two or more prior treatments received temozolomide at a dose of 150-200 mg m -2 per day on days 1-5 every 28 days. Results: From July 2012 to June 2016, 225 patients were screened, 80 showed MGMT promoter methylation and 41 were enrolled. Overall response rate was 10% and disease control rate was 32%. Median progression-free survival and overall survival were 1.9 and 5.1 months, respectively. Conclusions: Temozolomide showed a modest activity in this heavily pretreated population and the study did not meet its primary end point. The role of temozolomide in CRC remains still controversial and further research is warranted.

Calegari, M. A., Inno, A., Monterisi, S., Orlandi, A., Santini, D., Basso, M., Cassano, A., Martini, M., Cenci, T., De Pascalis, I., Camarda, F., Barbaro, B., Larocca, L. M., Gori, S., Tonini, G., Barone, C., A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation, <<BRITISH JOURNAL OF CANCER>>, 2017; 116 (10): 1279-1286. [doi:10.1038/bjc.2017.109] [http://hdl.handle.net/10807/169976]

A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation

Calegari, M. A.;Orlandi, A.;Cassano, A.;Martini, M.;Cenci, T.;De Pascalis, I.;Camarda, F.;Barbaro, B.;Larocca, L. M.;Barone, C.
2017

Abstract

Background: Presently, few options are available for refractory colorectal cancer (CRC). O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation is a frequent and early event in CRC tumourigenesis. This epigenetic silencing is a predictor of response to the alkylating drug temozolomide in glioblastoma. Preclinical evidences and some case reports showed temozolomide activity in CRC with MGMT silencing, but the available data from clinical trials are inconsistent. Methods: This was a multicentre, phase 2 trial, planned according to a two-stage Simon's optimal design to investigate activity and safety of temozolomide in refractory CRC harbouring MGMT promoter methylation. The primary end point was overall response rate (ORR). Patients who failed two or more prior treatments received temozolomide at a dose of 150-200 mg m -2 per day on days 1-5 every 28 days. Results: From July 2012 to June 2016, 225 patients were screened, 80 showed MGMT promoter methylation and 41 were enrolled. Overall response rate was 10% and disease control rate was 32%. Median progression-free survival and overall survival were 1.9 and 5.1 months, respectively. Conclusions: Temozolomide showed a modest activity in this heavily pretreated population and the study did not meet its primary end point. The role of temozolomide in CRC remains still controversial and further research is warranted.
Inglese
Calegari, M. A., Inno, A., Monterisi, S., Orlandi, A., Santini, D., Basso, M., Cassano, A., Martini, M., Cenci, T., De Pascalis, I., Camarda, F., Barbaro, B., Larocca, L. M., Gori, S., Tonini, G., Barone, C., A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation, <<BRITISH JOURNAL OF CANCER>>, 2017; 116 (10): 1279-1286. [doi:10.1038/bjc.2017.109] [http://hdl.handle.net/10807/169976]
File in questo prodotto:
File Dimensione Formato  
169976OA.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 799.74 kB
Formato Adobe PDF
799.74 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/169976
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 28
social impact